Get to know our clinical trials
Extension trial to evaluate the long-term efficacy and safety of prm-151 in patients with idiopathic pulmonary fibrosis.
THE PURPOSE OF THIS STUDY IS TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY (I.E., NEGATIVE AND POSITIVE EFFECTS) OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS.
- PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
- Code EudraCT: 2020-001429-30
- Protocol number: WA42294
- Promoter: Genentech, Inc.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.